US Stocks
Mersana Therapeutics Inc
Mersana Therapeutics Inc

Mersana Therapeutics Inc (MRSN)


  • $







Key Stats

Today Low/High$4.61 / $5.21
52 Week Low/High$4.64 / $24.38
Market Cap$367.47M

Company Details

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana's lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana's second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana's customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company's early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company's Immunosynthen platform. In addition, multiple partners are using Mersana's Dolaflexin platform to advance their ADC pipelines.
OrganisationMersana Therapeutics Inc
HeadquatersCambridge, Massachusetts, US
IndustryHealth Technology
CEONicholas Bacopoulos

Discover more

Frequently Asked Questions

What is Mersana Therapeutics Inc (MRSN) share price today?

Can Indians buy Mersana Therapeutics Inc (MRSN) shares?

How can I buy Mersana Therapeutics Inc (MRSN) shares from India?

Can Fractional shares of Mersana Therapeutics Inc (MRSN) be purchased?

What are the documents required to start investing in Mersana Therapeutics Inc (MRSN) stocks?